HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.

Abstract
Recombinant methioninase (rMETase) was previously administered as an injectable drug to target methionine dependence of cancer. Recently, we observed that rMETase could be administered orally (o-rMETase) in a patient-derived orthotopic xenograft (PDOX) mouse model of melanoma. Here, we determined the efficacy of o-rMETase on a pancreatic cancer PDOX model. Forty pancreatic cancer PDOX mouse models were randomized into four groups of 10 mice each. o-rMETase was significantly more effective than i.p.-rMETase, but the combination of both was significantly more effective than either alone. Acquired gemcitabine resistance is a major factor in the recalcitrance of pancreatic cancer. We tested a human pancreatic cancer cell line, which has acquired >100-fold GEM-resistance (PK-9R) than its parental cell line PK-9. In contrast to GEM, both cell lines were very sensitive to rMETase. In orthotopic nude mouse models of PK-9 and PK-9R, GEM inhibited tumor growth in PK-9 but not PK-9R. In contrast, o-rMETase could inhibit both tumors. The combination of GEM + o-rMETase could regress the PK-9 tumor and inhibit PK-9R tumor growth. The present study shows that o-rMETase is effective and overcomes acquired GEM resistance in pancreatic cancer and demonstrates the clinical potential of this strategy.
AuthorsKei Kawaguchi, Kentaro Miyake, Qinghong Han, Shukuan Li, Yuying Tan, Kentaro Igarashi, Tasuku Kiyuna, Masuyo Miyake, Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Sintawat Wangsiricharoen, Michael Bouvet, Shree Ram Singh, Michiaki Unno, Robert M Hoffman
JournalCancer letters (Cancer Lett) Vol. 432 Pg. 251-259 (09 28 2018) ISSN: 1872-7980 [Electronic] Ireland
PMID29928962 (Publication Type: Journal Article)
CopyrightPublished by Elsevier B.V.
Chemical References
  • Antimetabolites, Antineoplastic
  • Recombinant Proteins
  • Deoxycytidine
  • Carbon-Sulfur Lyases
  • L-methionine gamma-lyase
  • Gemcitabine
Topics
  • Administration, Oral
  • Animals
  • Antimetabolites, Antineoplastic (pharmacology)
  • Apoptosis
  • Carbon-Sulfur Lyases (administration & dosage)
  • Cell Proliferation
  • Deoxycytidine (analogs & derivatives, pharmacology)
  • Drug Resistance, Neoplasm
  • Humans
  • Injections, Intraperitoneal
  • Mice
  • Mice, Nude
  • Pancreatic Neoplasms (drug therapy, metabolism, pathology)
  • Recombinant Proteins (administration & dosage)
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: